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Purpose: The aim of this study was to compare the potency-stabilizing effects of two differ-
ent diluents of botulinum toxin A (10% dextrose solution and 0.9% saline).
Methods: A mouse lethality bioassay was undertaken. Ninety mice were divided into experi-
mental and control groups which received varying dosages in subgroups of 10. The experi-
mental group was injected with botulinum toxin A diluted with 10% dextrose solution and 
the control group was injected with botulinum toxin A diluted with 0.9% saline. A 72 hours 
after intraperitoneal injection, the number of dead mice was counted to confirm median le-
thal dose (LD50) of each group.
Results: The value of LD50 in the experimental group was approximately 0.131 mL (1.31 U) 
and the value of LD50 in the control group was approximately 0.107 mL (1.07 U). The po-
tency preservation rate of the experimental group was estimated to be 93.5% and that of 
the control group was estimated to be 76.3%. 
Conclusions: Dilution with 10% dextrose solution displayed less potency loss than 0.9% sa-
line.
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INTRODUCTION
Botulinum toxin is a type of protein produced by Clostridium 
botulinum which acts on the presynaptic nerve endings and 
blocks acetylcholine secretion. The resulting muscle paresis 
effect is used clinically to treat a number of diseases related 
to overactive muscle activity.
Botulinum toxin is categorized immunologically into 
eight serotypes (A, B, C1, C2, D, E, F, and G), of which type 
A is recognized as having the highest efficacy. Botulinum 
toxin A was first isolated in the 1920’s and its neurotrans-
mitter-blocking activity was first documented in 1949. Type 
A toxin was first used for treating strabismus in monkeys in 
the 1970’s and then in humans starting in 1981 [1]. 
Botulinum toxin A is sold in a freeze-dried state and 
must be diluted prior to clinical use. Since potency of the 
toxin gradually decreases after dilution, manufacturers rec-
ommend that it should be used within 4 hours after dilution 
with 0.9% saline solution.
Potency after dilution may be affected not only by time, 
but also by the type of diluent. Mclellan et al. [2] used a 
mouse lethality assay to show that botulinum toxin A dilut-
ed with saline lost twice as much potency than did toxin di-
luted with buffer solution containing 0.2% gelatin. Schantz 
and Johnson [3] reported a loss of toxin stability resulting 
from dilution of botulinum toxin A and that diluents con-
taining gelatin or albumin could prevent such loss.
Most of the botulinum toxin products currently marketed 
in a powder form contain minute amounts of gelatin or al-
bumin as a stabilizer and are diluted with 0.9% saline prior 
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to clinical use without any safety issues. However, when the 
toxin is diluted with gelatin or albumin solution instead of 
saline to lessen potency loss, unexpected problems, such as 
antibody production, viral cross-infections, and allergic re-
actions may occur [4]. Studies on safe and stable diluents 
that minimize potency loss during and after dilution are 
therefore needed.
This study examines the suitability of 10% dextrose solu-
tion, widely used as intravenous solution, as a diluent for 
botulinum toxin A by comparing changes in potency when 
the toxin is diluted with 10% dextrose solution and when it 
is diluted with 0.9% saline.
MATERIALS AND METHODS
1. Animals 
A 7-to-8 week old female ICR mice weighing 18-22 g 
(G-Bio Co., Gwacheon, Korea) were used after at least 5 
days of adjustment prior to the experiment. All animals 
were managed according to the strict protocols of Yonsei 
Center of Clinical Study. The experiment was approved 
by Yonsei Hospital Animal Experiment Ethics Committee 
(IACUC no. 2012-0068).
2. Dilution and Injection of Botulinum Toxin
One hundred units (U) of botulinum toxin A products 
containing 0.5 mg human serum albumin stabilizer (Botox; 
Allergan Inc., Dublin, Ireland) were used with each diluent. 
A 20% dextrose solution (Huons Co., Seongnam, Korea) 
was diluted to 10% for the experimental group. A 0.9% sa-
line solution (Dai Han Pharm Co., Seoul, Korea) was used 
for the control group. Injections were carried out using 0.5 
mL insulin syringes (Omnican 50; B-Braun, Melsungen, 
Germany) via the left abdominal cavity. All dilutions and 
injections of Botox were carried out by one operator.
3. Preliminary Study (Additional Injection of 10% Dextrose 
Solution in Control Group)
In a preliminary study, effects of 10% dextrose additional 
injection following the injection of botulinum toxin A di-
luted with 0.9% saline solution were studied. Additional in-
jection of 0.15 mL of 10% dextrose solution resulted in a 
pronounced reduction in mortality rate from 90% to 60%, 
while 0.20 mL additional injection resulted in only minor 
reduction of mortality rate from 100% to 90% (Table 1). 
These results suggest that dextrose solution may act as an 
energy source, though only a small amount can significant-
ly reduce rates of mortality in 20 g mice.
4. Experimental Protocols
For the control group, a total of 40 mice, 10 for each of 
the 4 dosages, were used. One hundred U Botox were dilut-
ed with 10 mL of 0.9% saline solution and doses of 0.10 mL 
(1.0 U), 0.15 mL (1.5 U), 0.18 mL (1.8 U), and 0.20 mL (2.0 
U) were injected into 10 mice each and the same amount of 
10% dextrose solution was given with additional injection.
For the experimental group, a total of 50 mice were used. 
Ten were used for each of the 5 different dosages. One hun-
dred U Botox were diluted with 10 mL of 10% dextrose so-
lution. Five different dosages of 0.075 mL (0.75 U), 0.080 
mL (0.80 U), 0.100 mL (1.0 U), 0.125 mL (1.25 U), and 0.150 
mL (1.50 U) were given to 10 mice each.
To confirm no effect for either diluent solution on the 
mortality rate, either 0.20 mL of 0.9% saline or 0.20 mL of 
10% dextrose solution were given to 10 mice each via in-
jection into the left abdominal cavity.
5. Calculation of Lethal Dose (LD50) 
Assuming no potency loss immediately after dilution, in 
a 10 mL solution dilution of 100 U Botox, 0.10 mL injection 
is equivalent to 1 mouse unit. One mouse unit translates to 
a potency at median LD50 in a 20 g mouse.
In order to assess the potency of botulinum toxin A us-
ing the approximate LD50 of the control and experimental 
groups, record was made of the number of mice dead 72 
hours after abdominal injections. Mortality rates and LD50, 
using the Miller and Tainer method, were calculated [5].
Table 1. Mortality rate after botulinum toxin A injection with or 
without additional dextrose solution injection
Botulinum toxin A 
diluted with 0.9% 
saline dilution
Mortality rate (%) 
after 72 h with no 
further injection of 
10% dextrose solution 
(n=10)
Mortality rate (%) 
after 72 h with 10% 
dextrose solution 
injection (n=10)
0.15 mL (1.5 U) 90 60
0.20 mL (2.0 U) 100 90
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RESULTS
1. Mortality Rate and Conversions for LD50 in the Control 
Group (0.9% Saline)
A total of 40 mice were used for the control group. Ten 
were used for each of the 4 different dosages. Mortality 
rates after 72 hours were 20% for the 0.10 mL (1.0 U) dos-
age and 90% for 0.18 mL (1.8 U) (Table 2). For probit anal-
ysis, log-doses corresponding to the X-axis were calculated 
and the mortality rates were converted to probit for Y-axis 
values (Table 3). Conversion of mortality rate to probit was 
done using the probit conversion table [6].
2. Mortality Rate and Conversions for LD50 in the 
Experimental Group (10% Dextrose Solution)
A total of 50 mice, 10 for each of the 5 dosages, were 
used for the experimental group. Mortality rates after 72 
hours were 60% for the 0.1 mL (1.0 U) dosage, showing 
much higher potency than that of the control group (Table 
4). For the 0.075 mL (0.75 U) dosage the mortality rate was 
0%, so a correction using the formula 100 (0.25/n) with 
n=10, 100 (0.25/10)=2.5 was required before probit conver-
sion (Table 5) [7].
3. Calculation of LD50 in the Control (0.9% Saline) and 
Experimental (10% Dextrose Solution) Group
LD50 of the control group was approximately 0.107 mL 
(1.07 U) (Fig. 1) and LD50 of the experimental group was 
0.131 mL (1.31 U) (Fig. 2). Regression analysis results from 
the control and experimental groups yielded a p-value of 
less than 0.05, indicating statistical significance with a 95% 
confidence level. 
Injection of diluent-only resulted in zero mortality for 0.2 
mL of 0.9% saline and 0.2 mL of 10% dextrose solution, 
confirming no effect for either diluent solution on the mor-
tality rate. 
DISCUSSION 
Numerous studies have shown that potency of botulinum 
toxin stored in a diluted form gradually decreases [8-10]. 
Even the dilution process itself contributes to potency loss 
[2]. This potency loss may be due to a lack of stabilization 
function in 0.9% saline solution used as a diluting agent. 
Table 2. Number of dead mouse and mortality rate in the control 
group
Botulinum toxin A 
dosage (U)
Number of dead 
mouse after 72 h
Mortality rate (%)
0.10 mL (1.0 U) 2 20
0.15 mL (1.5 U) 6 60
0.18 mL (1.8 U) 9 90
0.20 mL (2.0 U) 9 90
Table 3. Conversions for LD50 in the control group 
Dose (U) Log dose Mortality rate (%) Probits
1.0 0 20 4.16
1.5 0.1761 60 5.25
1.8 0.2553 90 6.28
2.0 0.3030 90 6.28
LD, lethal dose.




Number of dead mice 
after 72 h
Mortality (%)
0.075 mL (0.75 U) 0 0
0.080 mL (0.80 U) 2 20
0.100 mL (1.00 U) 6 60
0.125 mL (1.25 U) 8 80
0.150 mL (1.50 U) 8 80
Table 5. Conversions for LD50 in the experimental group
Dose (U) Log dose Mortality rate (%) Corrected %a Probits
0.75 –0.1249 0 2.5 3.04
0.80 –0.0969 20 20 4.16
1.00 0 60 60 5.26
1.25 0.0969 80 80 5.84
1.50 0.1761 80 80 5.84
LD, lethal dose.
aCorrected % Formula for 0 and 100% mortality.
For 0% dead: 100 (0.25/n). For 100% dead: 100 (n-0.25/n). 
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Protein stabilizers, such as albumin or gelatins in a powder 
form are added by manufacturers to minimize the potency 
loss, but their stabilizing effects start to decrease as soon as 
diluting saline is added. 
This study compares the potency-stabilizing effect of two 
different diluents of botulinum toxin A (10% dextrose and 
0.9% saline) by examining the mortality rate of mouse and 
their LD50. 
Yun et al [11]. studied potency loss after saline dilution of 
two kinds of botulinum A toxins. They found that a 1 U in-
jection per mouse resulted in 0% mortality after 72 hours 
while a 2 U injection resulted in nearly LD50, indicating pro-
nounced potency loss after dilution. Manufacturers of botu-
linum toxins recommend mild dilution to avoid potency 
loss, but some studies have showed no clinical difference be-
tween vigorous dilution and mild dilution methods [12,13]. 
However, these studies did not use LD50. Operators of the 
present study decided to use mild dilution method to exclude 
potential potency loss due to mechanical force. 
LD50 values were 1.31 units for the 0.9% saline control 
group and 1.07 units for 10% dextrose experimental group, 
indicating 1.22 times more stabilizing effect in the dex-
trose dilution. Provided that the potency of the toxin was 
100 U before dilution, the potency of 1 vial would be 76.3 U 
(100/1.31) for the control group and 93.5 U (100/1.07) for the 
experimental group. This indicates a potency retention rate 
of 76.3% for the control group and 93.5% for the experimen-
tal group. The higher potency retention of the experimental 
group might be a result of the function of dextrose as a pro-
tein stabilizer. Dextrose concentration may affect the extent 
of stabilization [14]. Due to the stronger stabilization effect 
of the 10% dextrose solution, potency loss can be reduced by 
using dextrose solution instead of saline as a diluent. 
Although measurement of mouse LD50 is generally con-
sidered an accurate and reliable method for assessing the 
potency of botulinum toxin [15], alternative methods are 
currently being investigated in order to reduce the large 
number of mice sacrificed by the LD50 bioassay.
In 1959, British biologists Russell and Burch published 
their seminal paper, The principles of humane experimen-
tal technique, which introduced ethical principles for ani-
mal experiments that are colloquially referred to as the ‘3 
Rs’: Replacement, Refinement and Reduction. Experiments 
using botulinum toxin on animals follow these principles. 
This study adhered to the principle of ‘reduction’ by trying 
to minimize the number of mice used. Other methods that 
may meet the ‘3 Rs’ requirements include mouse flaccid pa-
ralysis assay (mouse abdominal ptosis assay), hind limb pa-
ralysis assay, endopeptidase assay, and compound muscle 
action potential (CMAP) assay [16-18].
The systematic effect of mouse mortality rates may not 
accurately reflect local therapeutic effects. Dysport, for ex-
ample, requires a dose 3 to 4 times greater than that of 
Botox for similar results on muscles, which suggests that 
mouse LD50 alone would not be an appropriate indicator of 
human therapeutic effects. Mortality rate after 1 U injection 
Fig. 1. LD50 calculation of control group. Using regression equation 
Y=8.6999X+4.7389, X is calculated when Y is 5, and anti-LogX (Y=5) 
is 1.07 U.



















Fig. 2. LD50 calculation of experimental group. Using regression 
equation Y=7.4655X+4.1243, X is calculated when Y is 5, and anti-





















15Jong Wook Ham et al. Botulinum Toxin Dilution
www.journalomp.org
was 20% and 60% for the control and experimental groups 
respectively, yet it is difficult to conclude that actual clini-
cal efficacy would be three-fold. Similarly, the difference of 
22% in LD50 between the two groups may not correspond 
to a 22% difference in clinical results after muscular injec-
tion. Abdominally injected dextrose solution may also act 
as an energy source, contributing to the reduced mortality 
rate. Individual variability in reaction to abdominal injec-
tion may also affect the results. 
This study is a preliminary experiment to investigate the 
effects of different diluent solutions on local efficacy of 
botulinium A toxin. More specific comparison of local ef-
fects may require CMAP assay, mouse flaccid paralysis as-
say, or histological study as in Kim et al. [19].
This study compares the potency-stabilizing effect of two 
different diluents of botulinum toxin A (10% dextrose and 
0.9% saline) by examining the mortality rate of mouse and 
its LD50. The experiment group, injected with dextrose solu-
tion, displayed less potency loss than the control group in-
jected with a diluent of saline solution. These results suggest 
potential for improvement on the shortcomings of commonly 
used diluting methods. Further studies may need to compare 
the clinical efficacy of dextrose-diluted botulinum toxin.
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